Preclinical Evaluation of the Pharmacokinetics, Biodistribution, and Elimination of MS-325, a Blood Pool Agent for Magnetic Resonance Imaging
Authors:
- David J. ParmeleeDPDavid J. Parmelee
- Richard C. WalovitchRWRichard C. Walovitch
- Hillori S. OuelletHOHillori S. Ouellet
- Randall B. LaufferRLRandall B. Lauffer
- 1 December 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 32 (12) , 741-747
Abstract
The authors evaluate MS-325, a new albumin-targeted magnetic resonance imaging(MRI) contrast agent, for its pharmacokinetics, biodistribution, and elimination characteristics in multiple animal species. Studies were performed in rats, rabbits, and nonhuman primates at intravenous doses ranging from 0.025 to 0.20 mmol/kg. Concentrations of MS-325 in blood, urine, feces, and organs were determined using gadolinium-153-labeled MS-325 and gamma counting or by using non-labeled MS-325 and inductively coupled plasma atomic emission spectrometry. In rabbits and nonhuman primates, MS-325 is approximately 85% to 95% bound to serum proteins and, as a result, exhibits low volume of distribution (Vd) values, 0.11 to 0.14 L/kg, and a long elimination half-life (Te½), 2 to 3 hours. Some dose-dependence in the parameters is apparent in rabbits. MS-325 is eliminated primarily through the renal system in non-human primates. In contrast, the behavior of MS-325 in rats is different, exhibiting increased biliary excretion, a larger Vd value, and a shorter Te½. The pharmacokinetics and elimination profile of MS-325, including vascular retention and renal excretion, are favorable for use in humans as an intravascular contrast agent for MRI.Keywords
This publication has 10 references indexed in Scilit:
- Dynamic contrast‐enhanced MR imaging of the upper abdomen: Enhancement properties of gadobutrol, gadolinium‐DTPA‐polylysine, and gadolinium‐DTPA‐cascade‐polymerMagnetic Resonance in Medicine, 1994
- Quantisation of Saturation Effects versus Dose in Three-Dimensional Time-of-Flight Magnetic Resonance Angiography with Blood-Pool Contrast AgentsInvestigative Radiology, 1994
- Liver Contrast Media for Magnetic Resonance Imaging Interrelations between Pharmacokinetics and ImagingInvestigative Radiology, 1993
- A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies.Radiology, 1993
- Preclinical Safety Assessment and Pharmacokinetics of Gadodiamide Injection, a New Magnetic Resonance Imaging Contrast AgentInvestigative Radiology, 1993
- Atomic structure and chemistry of human serum albuminNature, 1992
- In vivo MR evaluation of Gd-DTPA conjugated to dextran in normal rabbitsMagnetic Resonance Imaging, 1992
- Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues.Radiology, 1990
- Comparison of the contrast-enhancing properties of albumin-(Gd-DTPA) and Gd-DTPA at 2.0 T: and experimental study in ratsAmerican Journal of Roentgenology, 1986
- Serum Albumin ‐ A Non‐Saturable CarrierActa Pharmacologica et Toxicologica, 1984